The Pharmacist

SEPTEMBER 4, 2023

The chief executive of the Royal College of Psychiatrists, Paul Rees, is to become the next chief executive of the National Pharmacy Association (NPA), it has been announced. The NPA has today confirmed the appointment of Mr Rees who will begin in post from 27 November. He will replace Mark Lyonette who is retiring after […] The post NPA announces appointment of new chief executive appeared first on The Pharmacist.

114

114

Drug Patent Watch

SEPTEMBER 4, 2023

Annual Drug Patent Expirations for SPINRAZA Spinraza is a drug marketed by Biogen Idec and is included in one NDA. It is available from one supplier. There are nine patents… The post New patent expiration for Biogen Idec drug SPINRAZA appeared first on DrugPatentWatch - Make Better Decisions.

97

97

The Pharmacist

SEPTEMBER 4, 2023

The government has launched a new consultation on how to make non-surgical cosmetic procedures, such as Botox and fillers, safer for the public in England. The move follows thousands of complaints around ‘botched’ procedures and aims to help inform a new licensing scheme for practitioners and cosmetic businesses. Launched over the weekend, the government is […] The post Government launches consultation on making cosmetic procedures safer appeared first on The Pharmacist.

103

103

Drug Patent Watch

SEPTEMBER 4, 2023

Annual Drug Patent Expirations for KYNAMRO Kynamro is a drug marketed by Kastle Theraps Llc and is included in one NDA. There are three patents protecting this drug. This drug… The post New patent expiration for Kastle Theraps drug KYNAMRO appeared first on DrugPatentWatch - Make Better Decisions.

96

96

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Pharmacist

SEPTEMBER 4, 2023

Limited quantities of Wegovy will be available in the UK for private and NHS supply from today, manufacturer Novo Nordisk has confirmed. But it expects supply to be ‘constrained for the foreseeable future’, with only some pharmacies launching a private Wegovy service today. There will also be a dedicated allocation of the weight-loss drug to […] The post ‘Controlled and limited launch’ of Wegovy from today appeared first on The Pharmacist.

96

96

Pharma Times

SEPTEMBER 4, 2023

The therapy has been developed for the treatment of Fabry disease among adult patients - News - PharmaTimes

118

118

Outsourcing Pharma

SEPTEMBER 4, 2023

The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnsonâs pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharma Times

SEPTEMBER 4, 2023

The therapy has been developed for the treatment of migraine among adults - News - PharmaTimes

122

122

European Pharmaceutical Review

SEPTEMBER 4, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Chiesi’s Elfabrio ® (pegunigalsidase alfa) for Fabry disease (alpha-galactosidase deficiency) in adults. A new Fabry disease treatment The agreement made in the NICE’s Final Draft Guidance means there is now a “new treatment option for people living with Fabry disease across England,” according to Dr Kamran Iqbal, Head of Medical Affairs for Global Rare Diseases at Chiesi UK&I. “Fabry disease brings a mu

89

89

Express Pharma

SEPTEMBER 4, 2023

International Journal of Pharmaceutics: In Vitro: The dissolution characteristics of five capsules (Next Generation Enteric [NGE], Vcaps® Enteric [VCE], VCE DUOCAP® [VCE/VCE] system, Hard Gelatin Capsule [HGC] as negative control, and Creon® 10,000 U as market reference) were evaluated using an in vitro simulation of the stomach and upper intestinal tract with an acidic duodenal incubation (pH 4.5 for the first 10 min, pH 6 for the remaining 17 min) to simulate exocrine pancreatic insufficiency.

85

85

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

European Pharmaceutical Review

SEPTEMBER 4, 2023

According to the US Federal Trade Commission (FTC), Amgen is to be barred from leveraging its drug portfolio to disadvantage its industry competitors. The biopharma company will be required to seek prior approval before acquiring related products. The FTC has settled on a proposed consent order with Amgen Inc. to address the potential competitive harm Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc could bring.

Biosimilars 83

Biosimilars 83

Express Pharma

SEPTEMBER 4, 2023

A notable shift is underway in the pharma industry as companies are increasingly prioritising the adoption of emerging technologies and stringent compliance measures to safeguard against cyber threats and data breaches. Consequently, there is a surge in hiring for cybersecurity-related roles including data, automation, security, compliance, risk, and relationships in Q2 2023, reflecting a 34 per cent compound annual growth rate since 2020, reveals the Job Analytics Database of GlobalData.

HIPAA 84

HIPAA Compounding 84

European Pharmaceutical Review

SEPTEMBER 4, 2023

Included in Issue 4 of European Pharmaceutical Review : FOREWORD Dissolution testing – a dual role David Elder, David P Elder Consultancy REGULATORY INSIGHT EU packaging reform: a prescription for change? Maciej Adamczyk and Monika Pyzio-Michalik, DBS Law Firm EVENT PREVIEW Modern methods in microbiology and analytics PharmaLab Congress DRUG DELIVERY Dry powder delivery to the lungs Jnanadeva Bhat, ACG EVENT PREVIEW CPHI Barcelona 2023: what to expect Featuring company profiles from BioSpectra,

Packaging 81

Packaging Vaccines Immunity Immunization 81

Outsourcing Pharma

SEPTEMBER 4, 2023

Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying off 40% of its workforce.

Drug Development 98

Drug Development 98

Pharmaceutical Technology

SEPTEMBER 4, 2023

iNtRON's contract is part of the US Army’s DEVCOM strategy to develop drugs to treat antibiotic-resistant UTIs.

98

98

Outsourcing Pharma

SEPTEMBER 4, 2023

The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.

97

97

pharmaphorum

SEPTEMBER 4, 2023

Patient involvement at NICE: In whose interest is it anyway? Mike.

107

107

Drug Patent Watch

SEPTEMBER 4, 2023

Annual Drug Patent Expirations for QUTENZA Qutenza is a drug marketed by Averitas and is included in one NDA. It is available from one supplier. There are seven patents protecting… The post New patent expiration for Averitas drug QUTENZA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

SEPTEMBER 4, 2023

Ergomed aims to go private via £703m Permira takeover Phil.

109

109

Drug Patent Watch

SEPTEMBER 4, 2023

Annual Drug Patent Expirations for TEGSEDI Tegsedi is a drug marketed by Akcea Theraps and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Akcea Theraps drug TEGSEDI appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

SEPTEMBER 4, 2023

Wegovy finally reaches the UK, in 'limited' quantities Phil.

103

103

Pharmafile

SEPTEMBER 4, 2023

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited launch. The drug is intended to provide new treatment options to patients living with obesity. The drug will now be available via specialist NHS weight management services for patients meeting the National Institute for Health […] The post Novo Nordisk launches Wegovy in the UK appeared first on Pharmafile.

58

58

pharmaphorum

SEPTEMBER 4, 2023

Roche seeks early-stage lung cancer use for Alecensa Phil.

99

99

Pharmafile

SEPTEMBER 4, 2023

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) who have already had one prior therapy. The National Medical Products Administration’s (NMPA) approval of this next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor follows positive results from […] The post AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemi

58

58

Pharmaceutical Technology

SEPTEMBER 4, 2023

The Japanese MHLW has accepted GSK’s supplementary new drug application (sJNDA) for Nucala (mepolizumab) to treat chronic rhinosinusitis

64

64

Outsourcing Pharma

SEPTEMBER 4, 2023

Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the companyâs origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning among many other topics.

52

52

Express Pharma

SEPTEMBER 4, 2023

Invivo: Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach. However, an enteric formulation is often accompanied with a higher development effort in the first place and the potential degradation of fragile APIs during the coating process. Ready-to-use enteric hard capsules would be an easily available alternative to test and develop APIs in enteric formulations, while decreasing the time and cost of pro

Dosage 52

Dosage 52

Pharmaceutical Business Review

SEPTEMBER 4, 2023

The company will utilise proceeds from the round for further developing its technology platform to accelerate its lead programmes to clinical stage. The participants in the financing round consist of TG Sino-Dragon Fund, Yunion Healthcare Ventures, Vision Plus Capital, Elikon Venture, as well as other industry and private individuals. Innovac CEO and co-founder Michael Zhang said: “We are thrilled with the great support from our investors.

Vaccines 52

Vaccines 52

Express Pharma

SEPTEMBER 4, 2023

Introducing Lonza Capsules & Health Ingredients’ groundbreaking enteric manufacturing technology – the Capsugel® Enprotect® capsule. This unique bi-layer capsule with the Coni-Snap® secure closure design utilizes HPMC and HPMC-AS polymers. It protects acid-sensitive APIs and enables rapid dissolution release at pH 6.8 without the need for additional excipients.

Drug Development 52

Drug Development 52

PharmaTech

SEPTEMBER 4, 2023

This executive summary highlights strategies that can be used to maximize long-acting parenteral formulations using nanoparticles, microspheres and in-situ forming gels.

52

52

Express Pharma

SEPTEMBER 4, 2023

Samsung Bioepis and Organon recently announced positive topline results from a Phase IV clinical trial of SB5, a biosimilar to the reference tumor necrosis factor (TNF) blocker Humira (adalimumab), in patients with moderate-to-severe chronic plaque psoriasis (PsO). The study met its primary endpoint of comparable pharmacokinetic profiles between SB5 and Humira, and showed comparable efficacy, safety, and immunogenicity profiles.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

SEPTEMBER 4, 2023

The company published a study showing lyso-Gb1 (glucosylsphingosine) as a diagnostic and predictive biomarker for the rare metabolic disease.

52

52

Pharma and Life Sciences Blog

SEPTEMBER 4, 2023

GEP is a leading global provider of AI-powered consulting, outsourcing and technology solutions to procurement and supply chain organizations at Fortune 500 and Global 2000 enterprises worldwide.

40

40

Pharmaceutical Technology

SEPTEMBER 4, 2023

Bidco has signed an agreement to acquire British biopharmaceutical services company Ergomed in a deal valued at about GBP703.1m ($884.79m).

52

52

PharmaTech

SEPTEMBER 4, 2023

Webinar Date/Time: Thursday, October 12, 2023 at 11am EDT | 4pm BST | 5pm CEST

52

52